Stroke and Tocotrienol: Unique Role in Neuroprotection "SATURN"

Recruiting

Phase 3 Results N/A

Summary of Purpose

Phase III, single-centre, double-blind, randomised, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of oral Vitamin E (Mixed Tocotrienol) for 6 months in patients with moderate ischemic stroke. 150 patients will be recruited. Half will receive mixed tocotrienol 200mg twice a day for 6 months while the other half will receive placebo capsules.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 9 December 2015.

1 Jul 2015 23 Sep 2014 1 Dec 2017 1 Dec 2018 1 Dec 2015 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts